The rule was based on feedback from the private sector, and resulted in the repeal of the nearly hundred million dollar annual mandate.
Based on the cost-benefit analysis performed by FDA, the rule will impose an unfunded mandate on the private sector of over $100 million annually and therefore the rule is subject to the requirements of the Act.